Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 741-750

  Koren, Michael J ^a   Davidson, Michael H ^b   Wilson, Daniel J ^c   Fayyad, Rana S ^c   Zuckerman, Andrea ^c   Reed, David P ^c  

^a Jacksonville Center for Clinical Research   (United States)

^b Pritzker School of Medicine   (United States)

^c PFIZER INC   (United States)

Author keywords

Chronic kidney disease (CKD); coronary heart disease (CHD); kidney function; statins

Indexed keywords

ATORVASTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MYOPATHY; OUTCOME ASSESSMENT; PATHOGENESIS; POST HOC ANALYSIS; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

AGED; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEALTH MAINTENANCE ORGANIZATIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 64749101006     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.025     Document Type: Article

References (28)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
2. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S266
3. US Renal Data System. USRDS 2007 Annual Data Report (2007), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
4. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
5. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
6. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?. National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
7. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
8. Parikh N.I., Hwang S.J., Larson M.G., Meigs J.B., Levy D., and Fox C.S. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med 166 (2006) 1884-1891
9. Charytan D., and Kuntz R.E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70 (2006) 2021-2030
10. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
11. Shepherd J., Kastelein J.J.P., Bittner V., et al., TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The Treating to New Targets (TNT) Study. J Am Coll Cardiol 51 (2008) 1448-1454
12. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
13. Tonelli M., Moye L., Sacks F.M., Cole T., and Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 (2003) 1605-1613
14. Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
15. Bianchi S., Bigazzi R., Caiazza A., and Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565-570
16. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. J Clin Pathol 57 (2004) 728-734
17. Shepherd J., Kastelein J.J.P., Bittner V., et al., TNT (Treating to New Targets) Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2 (2007) 1131-1139
18. Koren M.J., Hunninghake D.B., and ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE Study. J Am Coll Cardiol 44 (2004) 1772-1779
19. Isaacsohn J.L., Davidson M.H., Hunninghake D., Singer R., McLain R., and Black D.M. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol 86 (2000) 250-252
20. Brosius III F.C., Hostetter T.H., Kelepouris E., et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation 114 (2006) 1083-1087
21. Levey A.S., Greene T., Kusek J., Beck G., and MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 0828A (abstr)
22. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
23. Rahman M., Baimbridge C., Davis B.R., et al., ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 52 (2008) 412-424
24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
25. Moorhead J.F. Lipids and progressive kidney disease. Kidney Int Suppl 31 (1991) S35-S40
26. Epstein M., and Campese V.M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 45 (2005) 2-14
27. Stern R.H., Yang B.B., Horton M., Moore S., Abel R.B., and Olson S.C. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37 (1997) 816-819
28. Lins R.L., Matthys K.E., Verpooten G.A., et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 18 (2003) 967-976